A range of medications are available to help treat lupus nephritis (LN), each offering a specific role in managing the ...
Lupus nephritis (LN) diagnosis could improve greatly if early results with a multimarker urine test are confirmed in larger ...
1 The purpose of ALMS was to demonstrate the superiority of mycophenolate mofetil (MMF) over intravenous cyclophosphamide for the induction of remission in patients with lupus nephritis.
Lupus nephritis is an inflammatory kidney disease (glomerulonephritis) that develops in patients with systemic lupus erythematosus (SLE). In patients with SLE, the immune system is not properly ...
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) commends the American College of Rheumatology (ACR) for their 2024 evidence-based guidelines for the screening, treatment, and ...
Aurinia Pharmaceuticals (AUPH) has released an update. Aurinia Pharmaceuticals has unveiled new data underscoring the importance of early ...
Regular assessment of renal function, proteinuria, and serological markers is crucial for monitoring lupus nephritis progression and treatment response. Long-term follow-up data offer valuable ...
Amit Saxena, MD, discusses how personalized treatment decisions for lupus nephritis require careful consideration of patient characteristics, multidisciplinary coordination, and emerging guidelines, ...
Attendees can also look forward to the unveiling of new lupus nephritis guidelines, reflecting over a year of effort by experts. Additionally, there will be sessions on the potential of cell ...
Objective Lupus nephritis (LN) is a major cause of morbidity and mortality, affecting up to 60% of patients with systemic lupus erythematosus (SLE). The perspectives of patients with SLE have been ...
GlaxoSmithKline (GSK) has agreed to acquire Chimagen Biosciences’ CMG1A46, a clinical-stage therapy designed to target B cell-driven autoimmune diseases, for $300m upfront. The acquisition of CMG1A46, ...